Revelation Biosciences presented new data from its PRIME Study at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego on March 30 2026. The presentation showed that a single dose of Gemini durably normalizes cellular inflammation and restores immunocompetence in patients with stage 3 and 4 chronic kidney disease for up to seven days.
The data revealed that more than 85 % of participants had elevated cytokines before dosing, and over 60 % had elevated IL‑1β and IL‑6. Gemini significantly reduced these elevated cytokines and restored lipopolysaccharide responsiveness, extending earlier PRIME Study findings that the drug was safe and well‑tolerated in a Phase 1b trial.
While the results are encouraging, they represent an early clinical milestone and do not yet translate into efficacy outcomes such as dialysis avoidance or reduced hospital stay. The data provide early evidence that Gemini may address the hyperinflammatory state seen in advanced CKD patients.
Revelation is a clinical‑stage biotechnology company with no revenue, a negative earnings‑per‑share figure, a high cash burn rate, and an Altman Z‑Score of 0, indicating financial distress. The positive data may help attract future funding, but the company’s current financial position remains challenging.
The company will continue to pursue further trials, including an upcoming FDA end‑of‑Phase 1 meeting for the acute kidney injury indication and a single Phase 2/3 adaptive study for AKI. Gemini is a toll‑like receptor 4 agonist that reprograms the innate immune system to reduce inflammation and restore immunocompetence.
Investors have historically reacted cautiously to clinical milestones for Revelation, often due to the company’s high cash burn and lack of revenue. The positive data is a significant milestone but must be weighed against the company’s financial challenges.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.